Larimar Therapeutics (LRMR) · nomlabofusp
Later window · A neutral label from comparing the two stated windows. It says nothing about the program’s results.
Before
Stated timing: June 2026
We are targeting nomlabofusp BLA submission in June 2026 seeking accelerated approval using tissue FXN levels as a novel surrogate endpoint.
· filed · SEC filing
After
Stated timing: second half of 2026
plan to submit the CMC portion of the BLA in the second half of 2026
EX-99.1 · filed · SEC filing
Data as of . Both sentences are quoted from the SEC filings linked above and matched to them.
Source: ORION, orionbiotechai.com/changes/LRMR-nomlabofusp-2026-05-14, data as of Oct 13, 2026
https://www.orionbiotechai.com/changes/LRMR-nomlabofusp-2026-05-14
Larimar Therapeutics (LRMR) pipeline and stated timing · Calendar · Companies A–Z
A Form 10-K is a company’s annual report to the SEC, with audited financial statements.